J&J Secures Option on Sail’s In Vivo CAR-T Platform

Company Johnson & Johnson / Sail Biomedicines Event Type Strategic Collaboration, Equity Investment, and Exclusive Acquisition Option Modality Targeted-LNP delivery of stabilized circular RNA for transient in vivo CAR expression Asset SAIL-0804 (anti-CD19 in vivo CAR-T) and broader Endless RNA platform Target CD19 (lead candidate);…